Skip to main content

Generics

  • HDA to host annual Traceability Seminar

    ARLINGTON, Va. — The Healthcare Distribution Alliance (HDA, formerly HDMA) will host its annual Traceability Seminar Nov. 9–11, 2016, at the Renaissance Washington, DC Downtown Hotel. The seminar will host supply chain leaders — including distributors, manufacturers, pharmacists and third-party logistics providers — as well as federal/state regulators to discuss upcoming milestones and lessons learned as they continue to implement the Drug Supply Chain Security Act.


  • Teva launches Rajani, its Beyaz generic
    JERUSALEM — Teva on Wednesday announced the U.S. launch of its Rajani (drospirenone, ethinyl estradiol and levomefolate calcium tablets 3 mg/0.02 mg/0.451 mg and levomefolate calcium tablets 0.451 mg), a generic of oral contraceptive Beyaz. 
     
    Teva’s Rajani will be available in 28-day blister packs. The drug had $133 million in U.S. sales for the 12 months ended July 2016, according to IMS Health. 
     

  • Dr. Reddy’s launches generic Lamictal ODT
    HYDERABAD, India and PRINCETON, N.J. — Dr. Reddy’s Laboratories on Monday announced the U.S. launch of its generic of Lamictal (lamotrigine) ODT orally disintegrating tablets. 
     
    The Dr. Reddy’s generic will be available in 25-, 50-, 100- and 200-mg dosage strengths in 30-count bottles. The drug had U.S. sales of $65.5 million for the 12 months ending July 2016, according to IMS Health. 
     

  • HDA Research Foundation names new COO

    ARLINGTON, Va. – The HDA Research Foundation (formerly the Center for Healthcare Supply Chain Research) on Thursday named Perry Fri its new COO. He assumes leadership of the Foundation, the 501(c)(3) non-profit charitable organization of the Healthcare Distribution Alliance (HDA, formerly HDMA), from Karen Ribler, who retired at the end of September.

  • Teva, Celltrion partner on biosimilar commercialization
    JERUSALEM and INCHEON, South Korea — Teva and Celltrion on Thursday announced a new exclusive partnership centered on commercializing two of Celltrion’s biosimilar candidates in the United States and Canada. 
     

  • Teva to sell certain Actavis Generics assets in UK, Ireland
    JERUSALEM — Teva Pharmaceutical announced Wednesday that it would be selling certain assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare. The divestment, valued at about $769 million (£603 million), is part of an undertaking associated with the European Commission’s review of Teva’s acquisition of Actavis Generics. 
     

  • Report: Supreme Court won’t hear generics patent infringement suit

  • Fred’s renames Eiris Health Services as EntrustRx
    MEMPHIS, Tenn. — Fred’s announced Monday that its wholly-owned specialty pharmacy, Eiris Health Services has a new name. 
     
    Now, the operation will be known as EntrustRx, and the company said it will continue to provide patients holistic pharmaceutical care and therapies with a personal touch. 
     
X
This ad will auto-close in 10 seconds